India, Aug. 18 -- Nasus Pharma Ltd. (NSRX), a clinical-stage pharmaceutical company, on Monday released financial results for the first half of 2026, and highlighted a wider net loss due to increased costs of clinical drug development.
The company began trading on the New York Stock Exchange about a year ago, and has been advancing its lead drug candidate NS-002. The drug is formulated as an intranasal epinephrine powder for anaphylaxis in Type 1 allergic reactions.
H2 Financial Updates:
For the six months ending June 30, 2026, Nasus incurred a net loss of $5.94 million or $0.54 per share, compared to $1.25 million or $0.17 per share in the same period of the previous year.
The company recorded Research and Development (R&D) expenses at...